SCHEMBL14737148

SCHEMBL14737148

COc1ccc(-c2cccc3c2CNC3=O)c(OCC2(OC(=O)C3CCCCC3)CC2)c1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.35
KDR P35968 5/20 0.33
PDE4A P27815 2/20 0.33
TP53 P04637 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
PLK4 O00444 1/20 0.33
AURKA O14965 1/20 0.33
ROCK2 O75116 1/20 0.33
MAP4K4 O95819 1/20 0.33
ABL1 P00519 1/20 0.33
NTRK1 P04629 1/20 0.33
LCK P06239 1/20 0.33
CDK1 P06493 1/20 0.33
CSF1R P07333 1/20 0.33
LYN P07948 1/20 0.33
RET P07949 1/20 0.33
MET P08581 1/20 0.33
ROS1 P08922 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14738984 0.99 KDR (0.34) HPGDKDRPDE4ATP53HDAC4
SCHEMBL14738264 0.97 KDR (0.34) HPGDKDRPDE4AHDAC4HDAC2
SCHEMBL14737981 0.96 KDR (0.35) HPGDKDRHDAC4HDAC2HDAC8
SCHEMBL14737244 0.92 GSK3B (0.35) KDRHDAC4HDAC2HDAC8PLK4
SCHEMBL2592409 0.88 HPGD (0.36) HPGDKDRPDE4AHDAC4HDAC2
SCHEMBL2593001 0.87 KDR (0.36) KDRHDAC4HDAC2HDAC8PLK4
SCHEMBL2592970 0.87 ALDH1A1 (0.44) HPGDTP53HDAC4HDAC2HDAC8
SCHEMBL2587930 0.87 ALDH1A1 (0.44) HPGDTP53HDAC4HDAC2HDAC8
SCHEMBL14734796 0.86 KDR (0.35) KDRHDAC4HDAC2HDAC8PLK4
SCHEMBL14738155 0.85 PDE4D (0.37) HDAC4HDAC2HDAC8LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A HPGD 1088/4885KDR 1971/4885PDE4A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.